^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | JNJ-8177 (Tubulin inhibitor, PSMA-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
FDA Grants Fast Track Designation for Ambrx’s ARX517 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Published date:
07/19/2023
Excerpt:
Ambrx Biopharma...announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Ambrx’s proprietary anti-PSMA antibody-drug conjugate (ADC) investigational therapy, ARX517, for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) upon progression on an androgen receptor pathway inhibitor.
